Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25104683 | 0.81 | ATP4A (0.34) | CYP3A4CYP2C9CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL25539251 | 0.81 | AKT1 (0.34) | CYP3A4CYP2C9CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL25103350 | 0.79 | NMT1 (0.33) | CYP3A4CYP2C9 | |
| SCHEMBL7498143 | 0.75 | CYP3A4 (0.34) | CYP3A4CYP2C9CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL25260596 | 0.73 | PIM1 (0.31) | — | |
| SCHEMBL25311595 | 0.72 | MAPT (0.38) | CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL25311318 | 0.71 | PRMT5 (0.30) | — | |
| Hydrochloric Acid SCHEMBL31534499 | 0.71 | CYP3A4 (0.52) | CYP3A4CYP2C9CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL24656096 | 0.70 | CYP3A4 (0.33) | CYP3A4CYP2C9CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL6352105 | 0.70 | CYP3A4 (0.33) | CYP3A4CYP2C9CYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092066-A1 | SUBSTITUTED BICYCLIC HETEROCYCLES AS MALT-1 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2025-03-20 | — | — | US | disclosed |
| EP-4466268-A1 | SUBSTITUTED BICYCLIC HETEROCYCLES AS MALT-1 INHIBITORS | Aurigene Oncology Limited (IN) | 2024-11-27 | — | — | EP | disclosed |
| WO-2024182778-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| CN-118591541-A | Substituted bicyclic heterocycles as MALT-1 inhibitors | 奥瑞基尼肿瘤有限公司 | 2024-09-03 | — | — | CN | disclosed |
| WO-2023139479-A1 | SUBSTITUTED BICYCLIC HETEROCYCLES AS MALT-1 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023034812-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092066-A1 | SUBSTITUTED BICYCLIC HETEROCYCLES AS MALT-1 INHIBITORS | MALT1, FKBP1B, FKBP1A | CYP3A4 317/4885CYP2C9 828/4885CYP1A2 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.